General FDA approves daraxonrasib for patients with metastatic pancreatic cancerBy Healthcare Propulsion StaffAugust 29, 20260 The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts…
General FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-FarberBy Healthcare Propulsion StaffAugust 29, 20260 The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic…
